Physician profile
John B Kalis
NPI 1720061526
$4,539.13
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $415 · 2021: $591 · 2022: $1,185 · 2023: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.94 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $517.90 | 2019-2023 | |
| Biofrontera INC. | $449.78 | 2019-2022 | |
| Janssen Biotech, INC. | $433.44 | 2019-2023 | Remicade, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $399.72 | 2019-2023 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $252.18 | 2019-2023 | Winlevi, Absorica Ld |
| Amgen INC. | $211.17 | 2020-2023 | Otezla |
| Genzyme Corporation | $202.00 | 2019-2022 | |
| Lilly USA, LLC | $183.00 | 2019-2023 | Taltz, Olumiant |
| Pfizer INC. | $137.25 | 2019-2022 | |
| Galderma Laboratories, L.P. | $132.83 | 2019-2023 | Aklief, Oracea, Epsolay |
| Ucb, INC. | $125.88 | 2019-2022 | |
| Leo Pharma INC. | $119.10 | 2020-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.16 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $104.08 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $94.77 | 2022-2023 | Opzelura |
| Vyne Pharmaceuticals INC. | $72.33 | 2020-2021 | |
| Strata Skin Sciences, INC. | $59.11 | 2021 | |
| Dermavant Sciences, INC. | $57.53 | 2023 | Vtama |
| Epi Health, LLC | $40.36 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $38.94 | 2019 | |
| Almirall LLC | $35.85 | 2020-2021 | |
| Dusa Pharmaceuticals, INC. | $21.44 | 2019 | |
| Aclaris Therapeutics, INC. | $19.15 | 2019 | |
| Kyowa Kirin, INC. | $17.69 | 2022 | |
| Celgene Corporation | $17.41 | 2019 | |
| Sebela Pharmaceuticals INC. | $16.37 | 2022 | |
| Mission Pharmacal Company | $15.81 | 2020 | |
| Arcutis Biotherapeutics, INC. | $13.17 | 2023 | |
| Mylan Pharmaceuticals INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kalis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.